Source comparison
ARA-290 Dosage Comparison by Research Application
Diabetic Neuropathy (Human Clinical) 4 mg Subcutaneous Daily Standard dose from Diabetes Care Phase II trial; 28-day protocols Acute Kidney Injury (Human Clinical) 2.4 mg/kg (168 mg for 70 kg) Intravenous infusion 3× weekly Administered over 4–6 hours; used in
This comparison does not assign a generated winner or score.
- Diabetic Neuropathy (Human Clinical)
- 4 mg
- Subcutaneous
- Daily
- Standard dose from Diabetes Care Phase II trial; 28-day protocols
- Acute Kidney Injury (Human Clinical)
- 2.4 mg/kg (168 mg for 70 kg)
- Intravenous infusion
- 3× weekly
- Administered over 4–6 hours; used in ICU settings
- Neuroprotection Rodent Model
- 2 mg/kg
- Rat dose; rotate injection sites to prevent irritation
- Small Neuropathy Mouse Model
- 1.5–2 mg/kg
- Daily or 3× weekly
- Requires precise low-volume measurement (0.02–0.05 mL per dose)
- Tissue Repair In Vivo Study
- 1–3 mg/kg
- Dose-response studies vary; 2 mg/kg is most common baseline
- The comparison reveals a clear pattern: clinical trials favor daily 4 mg subcutaneous for chronic conditions and higher intravenous doses (2.4 mg/kg) for acute interventions. Rodent models use weight-based dosing at 1.5–2 mg/kg, typically three times weekly to balance efficacy with practical handling constraints. Researchers should match dosing frequency to the mechanism being studied. Tissue-protective signaling through the innate repair receptor peaks within hours of administration and declines within 24 hours, making daily or every-other-day dosing more mechanistically sound than weekly.